Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease

UB-312 was immunogenic in patients with early Parkinson’s disease. UB-312 was generally safe and well-tolerated. Results are consistent with conclusions from Phase 1 Part A and preclinical studies, and support advancement of UB-312 into further cl...

Related Keywords

Netherlands ,United States ,Texas ,Geert Jan Groeneveld ,Jon Yu ,Hoehn Yahr ,Mark Joinnides ,Nasdaq ,Centre For Human Drug Research ,Vaxxinity Inc ,Exchange Commission On ,European Medical Agency ,University Of Texas Houston ,Michaelj Fox Foundation ,Movement Disorders ,Human Drug Research ,Jan Groeneveld ,Clinical Neuropharmacology ,Leiden University Medical Center ,Mayo Clinic ,Texas Houston ,Human Drug ,Private Securities Litigation Reform Act ,Annual Report ,Exchange Commission ,